Effect of BTL-899 Device for Non-invasive Lipolysis on Human Upper Arms

Fat Burn Clinical Trial

Official title:

Effect of BTL-899 Device for Non-invasive Lipolysis on Human Upper Arms

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04643275
• Other study ID #: BTL-899A
• Status: Completed
• Phase: N/A
• Start date: October 15, 2020
• Est. completion date: September 2, 2021

Study information

• Verified date: September 2021
• Source: BTL Industries Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the clinical safety and the performance of the BTL-899 device during the treatment of upper arms.

Description:

The aim of the study is to confirm the efficacy and the safety of the treatment. The efficacy (reduction of excess adipose tissue) will be assessed via correct identification of pre-treatment and 3-months follow-up images by at least two out of three independent blinded evaluators. The fat reduction will be also measured by means of ultrasound. Comfort and satisfaction will be assessed via standard questionnaires.

Safety measures will include documentation of adverse events (AE) during and after the procedures.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Est. completion date: September 2, 2021
• Est. primary completion date: August 2, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 70 Years

Eligibility

Inclusion Criteria:

• Body Mass Index (BMI) of 20 to 35 kg/m2.

• Visible excess of adipose tissue at the treatment site

• Subjects willing and able to abstain from partaking in any treatments other than the study procedure to promote body contouring and/or weight loss during study participation.

• No procedure for fat reduction in the area in the last six months.

• Subjects willing and able to maintain his/her regular (pre-procedure) diet and exercise regimen without effecting a significant change of weight in either direction during the study participation.

Exclusion Criteria:

• Electronic implants (such as cardiac pacemakers, defibrillators, and neurostimulators)

• Cardiovascular diseases

• Vascular diseases (such as chronic venous insufficiency, deep venous thrombosis, varicose veins, etc.)

• Disturbance of temperature or pain perception

• Pulmonary insufficiency

• Metal implants

• Drug pumps

• Malignant tumor

• Hemorrhagic conditions

• Septic conditions and empyema

• Acute inflammations

• Systemic or local infection such as osteomyelitis and tuberculosis

• Contagious skin disease

• Elevated body temperature

• Pregnancy

• Breastfeeding

• Injured or otherwise impaired muscles in the arms

• Scars, open lesions, and wounds at the treatment area

• Basedow's disease

• Previous liposuction in the treatment area in the last six months

• Any other disease or condition at the investigator's discretion, e.g. dislocated shoulder or carpal tunnel syndrome than can pose danger to the patient or compromise the study

Related Conditions & MeSH terms

• Fat Burn

Intervention

Device:
• BTL-899
Treatment with study device.

Locations

Country	Name	City	State
Bulgaria	Dr Denkova Dermatology	Sofia

Sponsors (1)

Lead Sponsor	Collaborator
BTL Industries Ltd.

Country where clinical trial is conducted

Bulgaria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Statistically significant reduction of fat thickness in the upper arms evaluated by photographs	To gather clinical evidence that the BTL-899 device is able to induce non-invasive lipolysis when used on upper arms. The primary efficacy outcome measure is a minimum 75% of the subjects' pre-treatment and 3-months follow-up images to be correctly identified by at least two of three independent blinded evaluators.	5 months
Secondary	Evaluation of the Therapy's Safety Measured Via Therapy Comfort Questionnaire	Assessment the safety of the BTL-899 device when used for non-invasive lipolysis of the upper arms via questionnaires filled in by the participants following each therapy session. On Numerical Analog Scale (0-10), where 0 represents 'no pain' and 10 represents 'worst possible pain' select the level of pain experienced during the treatment. The outcome will further be measured through the occurrence of adverse events or lack thereof.	7 months
Secondary	Evaluation of the participants' satisfaction with the therapy evaluated via standard questionnaires	Evaluation of the participants' satisfaction with the therapy and the results. ? Minimum 80% of treated subjects to report satisfaction (level satisfied and higher) with the therapy.	5 months